Structure Therapeutics GPCR
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 99th percentile, 5-year average -17.1x
Near the bottom of its 5-year range · 11th percentile, 5-year average -316.8x
#1732 of 5330 stocks by PB (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 1.17 | – | -316.82 | 11% (cheaper than usual) | #1732 of 5330 (1 = cheapest) |
| PE | -5.13 | -2.41 | -17.13 | 99% (pricier than usual) | – |
| PS | – | 31.19 | 0.00 | – | – |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on GPCR.
Sign in to join the discussion.